Literature DB >> 15626757

Diagnostic tool for the identification of MLL rearrangements including unknown partner genes.

Claus Meyer1, Bjoern Schneider, Martin Reichel, Sieglinde Angermueller, Sabine Strehl, Susanne Schnittger, Claudia Schoch, Mieke W J C Jansen, Jacques J van Dongen, Rob Pieters, Oskar A Haas, Theo Dingermann, Thomas Klingebiel, Rolf Marschalek.   

Abstract

Approximately 50 different chromosomal translocations of the human MLL gene are currently known and associated with high-risk acute leukemia. The large number of different MLL translocation partner genes makes a precise diagnosis a demanding task. After their cytogenetic identification, only the most common MLL translocations are investigated by RT-PCR analyses, whereas infrequent or unknown MLL translocations are excluded from further analyses. Therefore, we aimed at establishing a method that enables the detection of any MLL rearrangement by using genomic DNA isolated from patient biopsy material. This goal was achieved by establishing a universal long-distance inverse-PCR approach that allows the identification of any kind of MLL rearrangement if located within the breakpoint cluster region. This method was applied to biopsy material derived from 40 leukemia patients known to carry MLL abnormalities. Thirty-six patients carried known MLL fusions (34 with der(11) and 2 with reciprocal alleles), whereas 3 patients were found to carry novel MLL fusions to ACACA, SELB, and SMAP1, respectively. One patient carried a genomic fusion between MLL and TIRAP, resulting from an interstitial deletion. Because of this interstitial deletion, portions of the MLL and TIRAP genes were deleted, together with 123 genes located within the 13-Mbp interval between both chromosomal loci. Therefore, this previously undescribed diagnostic tool has been proven successful for analyzing any MLL rearrangement including previously unrecognized partner genes. Furthermore, the determined patient-specific fusion sequences are useful for minimal residual disease monitoring of MLL associated acute leukemias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15626757      PMCID: PMC544299          DOI: 10.1073/pnas.0406994102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  MLL/SEPTIN6 chimeric transcript from inv ins(X;11)(q24;q23q13) in acute monocytic leukemia: report of a case and review of the literature.

Authors:  Hee-Jin Kim; Chang-Seok Ki; Quehn Park; Hong-Hoe Koo; Keon-Hee Yoo; Eun-Jeong Kim; Sun-Hee Kim
Journal:  Genes Chromosomes Cancer       Date:  2003-09       Impact factor: 5.006

2.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23).

Authors:  R B Lorsbach; J Moore; S Mathew; S C Raimondi; S T Mukatira; J R Downing
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

3.  Identification of CBL, a proto-oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia.

Authors:  Jen-Fen Fu; Jia-Jong Hsu; Tzung-Chih Tang; Lee-Yung Shih
Journal:  Genes Chromosomes Cancer       Date:  2003-06       Impact factor: 5.006

4.  A Saccharomyces cerevisiae mutant strain defective in acetyl-CoA carboxylase arrests at the G2/M phase of the cell cycle.

Authors:  Walid Al-Feel; James C DeMar; Salih J Wakil
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

5.  Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.

Authors:  Leslie J Raffini; Diana J Slater; Eric F Rappaport; Luca Lo Nigro; Nai-Kong V Cheung; Jaclyn A Biegel; Peter C Nowell; Beverly J Lange; Carolyn A Felix
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

6.  Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.

Authors:  Thorsten Langer; Markus Metzler; Dirk Reinhardt; Susanne Viehmann; Arndt Borkhardt; Martin Reichel; Martin Stanulla; Martin Schrappe; Ursula Creutzig; Jörg Ritter; Thomas Leis; Ulla Jacobs; Jochen Harbott; Jörn D Beck; Wolfgang Rascher; Reinald Repp
Journal:  Genes Chromosomes Cancer       Date:  2003-04       Impact factor: 5.006

7.  BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.

Authors:  Clémence Magnard; Richard Bachelier; Anne Vincent; Michel Jaquinod; Sylvie Kieffer; Gilbert M Lenoir; Nicole Dalla Venezia
Journal:  Oncogene       Date:  2002-10-03       Impact factor: 9.867

8.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

Authors:  Eng-Juh Yeoh; Mary E Ross; Sheila A Shurtleff; W Kent Williams; Divyen Patel; Rami Mahfouz; Fred G Behm; Susana C Raimondi; Mary V Relling; Anami Patel; Cheng Cheng; Dario Campana; Dawn Wilkins; Xiaodong Zhou; Jinyan Li; Huiqing Liu; Ching-Hon Pui; William E Evans; Clayton Naeve; Limsoon Wong; James R Downing
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

Review 9.  Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia.

Authors:  M van der Burg; T S Poulsen; S P Hunger; H B Beverloo; E M E Smit; K Vang-Nielsen; A W Langerak; J J M van Dongen
Journal:  Leukemia       Date:  2004-05       Impact factor: 11.528

10.  AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.

Authors:  Claudia Schoch; Susanne Schnittger; Mirjam Klaus; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

View more
  40 in total

1.  Diagnostic usefulness of genomic breakpoint analysis of various gene rearrangements in acute leukemias: a perspective of long distance- or long distance inverse-PCR-based approaches.

Authors:  John Jeongseok Yang; Rolf Marschalek; Claus Meyer; Tae Sung Park
Journal:  Ann Lab Med       Date:  2012-06-20       Impact factor: 3.464

2.  MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.

Authors:  Przemyslaw Juszczynski; Scott J Rodig; Jing Ouyang; Evan O'Donnell; Kunihiko Takeyama; Wojciech Mlynarski; Katarzyna Mycko; Tomasz Szczepanski; Anna Gaworczyk; Andrei Krivtsov; Joerg Faber; Amit U Sinha; Gabriel A Rabinovich; Scott A Armstrong; Jeffery L Kutok; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

3.  Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

Authors:  Brian V Balgobind; Marry M Van den Heuvel-Eibrink; Renee X De Menezes; Dirk Reinhardt; Iris H I M Hollink; Susan T J C M Arentsen-Peters; Elisabeth R van Wering; Gertjan J L Kaspers; Jacqueline Cloos; Evelien S J M de Bont; Jean-Michel Cayuela; Andre Baruchel; Claus Meyer; Rolf Marschalek; Jan Trka; Jan Stary; H Berna Beverloo; Rob Pieters; C Michel Zwaan; Monique L den Boer
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 4.  Contribution of AZAP-Type Arf GAPs to cancer cell migration and invasion.

Authors:  Vi Luan Ha; Ruibai Luo; Zhongzhen Nie; Paul A Randazzo
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

5.  Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia.

Authors:  Shunsuke Kon; Naoko Minegishi; Kenji Tanabe; Toshio Watanabe; Tomo Funaki; Won Fen Wong; Daisuke Sakamoto; Yudai Higuchi; Hiroshi Kiyonari; Katsutoshi Asano; Yoichiro Iwakura; Manabu Fukumoto; Motomi Osato; Masashi Sanada; Seishi Ogawa; Takuro Nakamura; Masanobu Satake
Journal:  J Clin Invest       Date:  2013-02-22       Impact factor: 14.808

6.  From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML.

Authors:  M Krumbholz; J Bradtke; D Stachel; O Peters; B Hero; W Holter; R Slany; M Metzler
Journal:  Bone Marrow Transplant       Date:  2015-07-06       Impact factor: 5.483

7.  Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia.

Authors:  Heiko Becker; Gabriele Greve; Keisuke Kataoka; Jan-Philipp Mallm; Jesús Duque-Afonso; Tobias Ma; Christoph Niemöller; Milena Pantic; Justus Duyster; Michael L Cleary; Julia Schüler; Karsten Rippe; Seishi Ogawa; Michael Lübbert
Journal:  Blood Adv       Date:  2019-03-12

8.  Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution.

Authors:  Nuno Cerveira; Susana Lisboa; Cecília Correia; Susana Bizarro; Joana Santos; Lurdes Torres; Joana Vieira; João D Barros-Silva; Dulcineia Pereira; Cláudia Moreira; Claus Meyer; Tereza Oliva; Ilídia Moreira; Ângelo Martins; Luísa Viterbo; Vítor Costa; Rolf Marschalek; Armando Pinto; José M Mariz; Manuel R Teixeira
Journal:  Mol Oncol       Date:  2012-07-14       Impact factor: 6.603

9.  Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach.

Authors:  Anke van Rijk; David Mason; Margaret Jones; José Cabeçadas; Mateus Crespo; Juan Cruz Cigudosa; Juan Fernando Garcia; Lorenzo Leoncini; Mario Cocco; Martin-Leo Hansmann; Anja Mottok; Christiane Copie Bergman; Maryse Baia; Dimitra Anagnostou; Evi Pouliou; Stephen Hamilton Dutoit; Mette Hjøllund Christiansen; Tim Svenstrup Poulsen; Steen Hauge Matthiesen; Jacques van Dongen; J Han van Krieken
Journal:  J Hematop       Date:  2008-08-29       Impact factor: 0.196

10.  Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.

Authors:  Sonja Röhrs; Wilhelm G Dirks; Claus Meyer; Rolf Marschalek; Michaela Scherr; Robert Slany; Andrew Wallace; Hans G Drexler; Hilmar Quentmeier
Journal:  Mol Cancer       Date:  2009-10-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.